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Abstract
Objective The objective of this study was to characterize
the impact of casopitant, a novel neurokinin-1 receptor
antagonist under investigation for the prevention of
postoperative and chemotherapy-induced nausea and vomit-
ing, on the pharmacokinetics of the commonly prescribed
5-hydroxytryptamine receptor 3 receptor antagonists,
dolasetron or granisetron.
Materials and methods In a phase I, open-label, two-part,
two-period, single-sequence study, two cohorts of healthy
subjects received either oral dolasetron (100 mg once daily
for 3 days) or oral granisetron (2 mg once daily for 3 days)
alone (period 1) and combined with oral casopitant, 150 mg
day 1, 50 mg days 2 and 3 (period 2). Pharmacokinetics of
hydrodolasetron and granisetron were assessed on days 1
and 3 of each period. Log-transformed area under the curve
(AUC) and Cmax were statistically analyzed by performing
an analysis of variance. Eighteen subjects were enrolled in
the dolasetron cohort; nine subjects were CYP2D6 exten-
sive metabolizers (EMs) and nine subjects were CYP2D6
poor metabolizers. Nineteen subjects were enrolled in the
granisetron cohort.
Results The largest changes in hydrodolasetron exposure
after coadministration with casopitant were seen in
CYP2D6 EMs, with a 24% increase in hydrodolasetron
AUC on day 1 and 30% increase in Cmax on days 1 and 3.
All other changes in hydrodolasetron exposure were <20%,
and granisetron exposure was not altered to any relevant
extent (<11%).
Conclusion None of the changes observed are considered
clinically meaningful, and coadministration of casopitant
with dolasetron or granisetron was well tolerated.
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Introduction
Emesis is an autonomic reflex controlled by multiple
neurotransmitter systems; two of the most important are
the serotonin/5-hydroxytryptamine receptor 3 (5-HT3) and
substance P/neurokinin-1 receptor (NK-1) systems [13].
Blocking both the 5-HT3 and NK-1 neurotransmitter
receptors has been demonstrated to prevent chemotherapy-
induced nausea and vomiting in patients receiving chemo-
therapy [6, 11, 12, 20, 29] .A c c o r d i n gt og u i d e l i n e s
established by the Multinational Association for Supportive
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San Diego, CA, USACare in Cancer [23], patients who will receive a moderately
emetogenic chemotherapy (MEC) regimen should receive a
5-HT3 receptor antagonist and dexamethasone for the
prevention of chemotherapy-induced nausea and vomiting
(CINV), while patients who will receive a MEC regimen
that includes anthracycline and cyclophosphamide or a
highly emetogenic chemotherapy (HEC) regimen should
receive a 5-HT3 receptor antagonist, a corticosteroid, and an
NK-1 receptor antagonist [23, 25].
NK-1 receptor antagonists have also shown efficacy in
the treatment and prevention of postoperative nausea and
vomiting (PONV), both alone and in combination with a 5-
HT3 receptor antagonist [7, 10, 28]. Without prophylactic
antiemetics, approximately 20–30% of surgical patients
experience PONV [18, 30], and, in the highest-risk patients,
PONV may occur in up to 70–80% of cases [1, 9].
Casopitant, a novel NK-1 receptor antagonist, is under
investigation as part of a three-drug antiemetic regimen
including a 5-HT3 receptor antagonist and corticosteroid for
patients receiving MEC or HEC. In clinical studies,
casopitant is a weak to moderate inhibitor of the drug-
metabolizing enzyme CYP3A (depending on dose and
duration of dosing) but does not appear to have any
significant impact on CYP2D6 after 50 or 100 mg single
oral doses of casopitant as assessed by the CYP2D6 probe,
debrisoquine (unpublished data, GlaxoSmithKline 2006).
In vivo, the 5-HT3 receptor antagonist dolasetron is
rapidly reduced (half-life of less than 15 min [17]) by
ubiquitous carbonyl reductases to its metabolically active
form, hydrodolasetron, which is largely responsible for the
pharmacologic activity ([3, 8] and references therein).
Hydrodolasetron is further metabolized by CYP2D6 with
minor involvement of CYP3A4 [26]. Plasma exposures of
hydrodolasetron are increased approximately threefold in
CYP2D6 poor metabolizers (PMs) as compared to exten-
sive metabolizers (EMs) [19]. For CYP2D6 PMs, CYP3A4
is likely to play a larger role in the clearance of hydro-
dolasetron, and these subjects may be more sensitive to
coadministration of inhibitors of CYP3A, such as casopi-
tant. In vitro, granisetron is primarily metabolized by
CYP1A1 and CYP3A4 [4, 24] and therefore plasma levels
of granisetron also may be increased when coadministered
with casopitant.
The aim of this study was to assess the impact of a 3-day
regimen of casopitant on the pharmacokinetics of repeat
doses of oral dolasetron (as assessed by hydrodolasetron
exposure) or granisetron. The pharmacokinetics of casopi-
tant were not assessed since neither (hydro)dolasetron nor
granisetron are significant inhibitors of cytochrome P450
(CYP) enzymes and are therefore unlikely to impact the
clinical pharmacokinetics of casopitant to any relevant
extent [2, 4]. In addition, acute, usually reversible, cardiac
effects including QTc prolongation have been observed
following dolasetron administration [2]. Arrhythmias such
as bradycardia have been observed with other 5-HT3
receptor antagonists, although to a lesser extent. Therefore,
a PK interaction that may lead to increased hydrodolasetron
or granisetron plasma concentrations has the potential to
increase the risk of electrocardiogram (ECG) abnormalities.
Therefore, this study also evaluated the potential for ECG
changes following administration of dolasetron or granisetron
with oral casopitant.
Subjects and methods
Subject population
Male and female subjects of 18 to 64 years of age, body
mass index of ≥19 to ≤37 kg/m
2, and adequate organ
function were eligible to enter the study. All females of
childbearing potential were required to use birth control
from 14 days before the first dose of study medication,
throughout the study, and for 14 days after the last dose of
study medication. Exclusion criteria were designed to
ensure that subjects were in good health and not receiving
concomitant medications that could interfere with the
pharmacokinetics of study medications.
For the dolasetron cohort, subjects were eligible only if
they were determined to be either CYP2D6 PMs (*3, *4,
*5, *6, or *7 homozygotes) or CYP2D6 EMs (absence or
heterozygotes for *3, *4, *5, *6, or *7 alleles and devoid of
CYP2D6 gene duplication) by genotypic analysis ([21]
Gentris, Morrisville NC, USA). Approximately an equal
number of CYP2D6 EMs and PMs were to be enrolled in
the dolasetron cohort of the study.
The study protocol and informed consent documents
were reviewed and approved by an institutional review
board and subjects provided written consent prior to
participation in the trial. All investigators were required to
abide by Good Clinical Practices, International Conference
on Harmonization guidelines, Declaration of Helsinki
principles, and local laws and regulations.
Study design
This was a phase I, open-label, two-part, two-period,
single-sequence study. Two cohorts of subjects received
either oral dolasetron (100 mg once daily for 3 days) or oral
granisetron (2 mg once daily for 3 days) alone (period 1)
and then combined (period 2) with oral casopitant (150 mg
day 1, 50 mg days 2 and 3). Each period was separated by a
window of 5 to 14 days. During period 2, casopitant was
coadministered at the same time with either dolasetron or
granisetron. All doses of study medication were taken after
at least a 2 h fasting period. Plasma pharmacokinetics of
1188 Support Care Cancer (2009) 17:1187–1193hydrodolasetron and granisetron were assessed on days 1
and 3 of each period with blood samples collected predose
and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 h postdose.
Safety was assessed through adverse-event reporting and
evaluation of clinical laboratory parameters and vital signs.
In both periods, 12-lead electrocardiograms were performed
on days 1 to 3 prior to administration of dolasetron or on
day 1 prior to administration of granisetron.
Pharmacokinetics
Human ethylenediaminetetraacetic acid plasma samples
(50 μL aliquot) were analyzed for hydrodolasetron or
granisetron using validated analytical methods based on
protein precipitation, followed by high-performance liquid
chromatography/mass spectrometry (MS)/MS analysis. For
hydrodolasetron, the lower and upper limits of quantifica-
tion were 1 and 1,000 ng/mL, respectively. For granisetron,
the lower and upper limits of quantification were 0.1 and
100 ng/mL, respectively. Quality control (QC) samples,
prepared at three different analyte concentrations and stored
with study samples, were analyzed with each batch of
samples against separately prepared calibration standards.
For the analysis to be acceptable, no more than one third of
the QC results were to deviate from the nominal concen-
tration by more than 15%, and at least 50% of the results
from each QC concentration should be within 15% of
nominal. The applicable analytical runs met all predefined
run acceptance criteria.
Pharmacokinetic parameters area under the curve
(AUC)(0-τ) and Cmax were determined on both days 1
and 3 in periods 1 and 2 using standard non-compartmental
methods (WinNonlin, version 4.1, Pharsight Corp, Moun-
tain View, CA, USA).
Statistics
An estimation approach was taken to determine the magni-
tude of the interaction between hydrodolasetron or granise-
tron and casopitant. AUC and Cmax were statistically
analyzed by performing an analysis of variance (ANOVA)
on log(e)-transformed datain order to compute an estimate of
the geometric least-square mean ratios and 90% confidence
intervals (CI) for AUC(0-τ) and Cmax comparing the test
treatment in period 2 (5HT3 + casopitant) to the reference
treatment in period 1 (5HT3 alone). No clinically meaning-
ful interaction effect was assumed if the 90% CI for the
mean ratio was completely within the interval of 0.8 to 1.25.
For the dolasetron cohort, the ANOVA used a mixed-
effects model with subject as a random effect and treatment,
day, and population (CYP2D6 EM or PM) as well as all
two- and three-way interactions of treatment, day, and
population as fixed effects. For the granisetron cohort, the
ANOVA used a mixed-effects model with subject as a
random effect and treatment, day, and treatment-by-day
interaction as fixed effects.
A sufficient number of subjects were enrolled to ensure
that at least 12 evaluable subjects completed each part of
the study. In the dolasetron arm, a minimum of six
CYP2D6 PMs and six EMs were to complete the study.
With the assumption that the within-subject coefficient of
variation (CV) is 41%, the lower and upper bounds of the
90% CI for the ratio of the geometric means for
pharmacokinetic parameters were calculated to be within
19% of the point estimates. This calculation was based on a
symmetric two-tailed procedure on the log(e) scale and a
type I error rate of 5% in each tail. In the granisetron arm,
with the assumption of the within-subject CV of 23%, a
sample size of 12 evaluable subjects, and similar analysis
procedure as described above, the lower and upper bounds
of the 90% CI were calculated to be within 10% of the
point estimates.
Results
A total of 18 healthy adult subjects were enrolled in the
dolasetron cohort; nine subjects were CYP2D6 EMs and
nine subjects were CYP2D6 PMs. A total of 19 healthy
adult subjects were enrolled in the granisetron cohort.
Demographic characteristics are summarized in Table 1.
Dolasetron
Coadministration of casopitant with dolasetron resulted in
slight increases in mean hydrodolasetron AUC and Cmax
on days 1 and 3, with no mean increase in exposure of more
than 25% (Table 2). All 90% CIs for hydrodolasetron AUC
ratios were within the range of 0.8 to 1.25; however, the
upper bound was exceeded for ratios of hydrodolasetron
Cmax. In the CYP2D6 EM population, there were 24% and
10% mean increases in hydrodolasetron AUC on days 1
and 3, respectively, and 30% mean increases in Cmax on
both days 1 and 3. CYP2D6 PMs exhibited approximately
twice the exposure to hydrodolasetron as CYP2D6 EMs
when dolasetron was administered alone (Fig. 1). However,
after coadministration with casopitant, CYP2D6 PMs
exhibited smaller changes in hydrodolasetron AUC and
Cmax compared to CYP2D6 EMs. For CYP2D6 PMs, only
the day 3 Cmax parameter ratio exceeded the predefined
90% CI range of 0.8 to 1.25, with a mean increase of 14%.
Granisetron
Coadministration of casopitant with granisetron resulted in
mean increases in granisetron AUC and Cmax of 11% or
Support Care Cancer (2009) 17:1187–1193 1189less (Table 2). The day 1 90% CIs for AUC and Cmax were
just outside the 0.8 to 1.25 interval, but the 90% CIs were
within the interval on day 3. Results from individual
subjects are illustrated in Fig. 2.
Safety
Coadministration of casopitant and dolasetron or granisetron
was well tolerated. Adverse-event frequencies are sum-
marized in Table 3. The most common adverse event was
headache which occurred at a lower frequency in
casopitant-containing regimens. When casopitant was
coadministered with dolasetron, the adverse-event profile
was similar to dolasetron administered alone. When
casopitant was coadministered with granisetron, the
incidence of somnolence increased and the incidence of
constipation decreased compared to granisetron adminis-
tered alone. All adverse events were mild or moderate in
intensity, and all events resolved. There were no serious
adverse events and no deaths. Changes in clinical
laboratory values, vital signs, and ECGs were not
clinically meaningful.
Table 1 Demographic characteristics of enrolled subjects
Characteristic Dolasetron cohort, n=18 Granisetron cohort, n=19
Age in years, mean (range) 30.3 (21–41) 41.3 (20–64)
Sex, n (%)
Female 1 (6%) 17 (89%)
Male 17 (94%) 2 (11%)
Height, cm (mean and range) 176.6 (168–190) 163.6 (156–180)
Weight, kg (mean and range) 88.41 (59.1–125) 70.2 (54.1–98.2)
BMI, kg/m
2 (mean and range) 28.25 (18.84–36.55) 26.14 (21.03–35.64)
Race, n (%)
African American/African heritage 3 (17%) 2 (11%)
White/Caucasian/European heritage 15 (83%) 16 (84%)
Mixed race 0 1 (5%)
Genotype, n (%)
Extensive metabolizers (EM) 9 (50%) NA
Poor metabolizers (PM) 9 (50%) NA
NA not applicable
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Fig. 1 Day 1 and day 3 hydro-
dolasetron AUC(0-τ) and Cmax
when a 3-day regimen of
100 mg oral dolasetron is given
alone and in combination with a
3-day oral regimen of casopitant
in CYP2D6 EMs (circles) and
CYP2D6 PMs (triangles)
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This study examined the potential for pharmacokinetic
interactions between oral casopitant and repeat-dose oral
dolasetron or granisetron using the highest oral dose of
casopitant currently under investigation for the prevention
of CINV, i.e., 150 mg on day 1, followed by 50 mg on
days 2 and 3. An intravenous formulation of 90 mg
casopitant is also under investigation; however, as oral
administration results in higher gut and liver concentrations
of study drug and these sites are known to have higher
concentrations of CYP enzymes and thus higher potential
CYP inhibition [16], less significant interactions would be
expected after intravenous administration of casopitant.
Clinical studies using coadministration of oral midazo-
lam have demonstrated that casopitant results in weak to
moderate inhibition of CYP3A in the oral dose range of 50
to 150 mg but no inhibition of CYP2D6 using debrisoquine
as a probe with single oral doses up to 100 mg and there is
no in vitro evidence that casopitant is a significant inhibitor
of CYP1A enzymes (unpublished data, GlaxoSmithKline).
The major circulating active metabolite of dolasetron,
hydrodolasetron, is metabolized by CYP2D6 and, to a
lesser extent, by CYP3A4. The current study showed that
coadministration of dolasetron with a 3-day regimen of
casopitant resulted in no clinically relevant change in the
exposure of hydrodolasetron. The largest observed changes
were a 14% increase in hydrodolasetron AUC on day 1 and
18% and 22% increases in hydrodolasetron Cmax on days 1
and 3, respectively. These changes are not considered
clinically relevant, were not associated with any increase in
adverse events, and were within the same range of within-
subject variability for dolasetron exposure (41% as de-
scribed in “Statistics”).
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Fig. 2 Day 1 and day 3 grani-
setron AUC(0-τ) and Cmax
when a 3-day regimen of 2 mg
oral granisetron is given alone
and in combination with a 3-day
oral regimen of casopitant
Table 2 Change in hydrodolasetron and granisetron AUC and Cmax when coadministered with casopitant (ratio of dolasetron or granisetron plus
casopitant to dolasetron or granisetron alone)
Analyte Population Day AUC ratio (90% CI) Cmax ratio (90% CI)
Hydrodolasetron All 1 1.14 (1.08, 1.20) 1.18 (1.06, 1.31)
3 1.07 (1.03, 1.13) 1.22 (1.10, 1.36)
CYP2D6 EMs 1 1.24 (1.15, 1.34) 1.30 (1.11, 1.53)
3 1.10 (1.02, 1.19) 1.31 (1.11, 1.53)
CYP2D6 PMs 1 1.05 (0.97, 1.12) 1.06 (0.92, 1.23)
3 1.05 (0.98, 1.12) 1.14 (0.99, 1.32)
Granisetron All 1 1.08 (0.93, 1.26) 1.11 (0.95, 1.29)
3 1.00 (0.86, 1.17) 1.04 (0.89, 1.22)
Support Care Cancer (2009) 17:1187–1193 1191CYP2D6 is responsible for a large proportion of hydro-
dolasetron clearance and is polymorphically expressed.
CYP2D6 PMs had only approximately twofold higher
hydrodolasetron exposure than CYP2D6 EMs in this study
(Fig. 1). There is a theoretical potential for increased
pharmacokinetic interaction between casopitant and hydro-
dolasetron in CYP2D6 PMs as CYP3A4 is likely to
comprise a larger proportion of hydrodolasetron clearance
in these subjects. The majority of the Caucasian population
(70%) would be classified as CYP2D6 EMs, requiring just
one copy of a functional CYP2D6 allele (*1 or *2);
however, 51% of the African American population are
EMs and 35% would be classified as reduced function or
intermediate metabolizers. The frequency of PM status
(non-functional alleles) is 5–10% in Caucasian populations
and 15% in African Americans [5].
The statistical analysis of hydrodolasetron exposure in
CYP2D6 EMs and PMs (Table 2) shows that CYP2D6 PMs
did not exhibit significant increases in hydrodolasetron
exposure when dolasetron was coadministered with caso-
pitant. Likewise in CYP2D6 EMs, although hydrodolase-
tron exposure was increased 10% (AUC) to 31% (Cmax),
these increases were not considered clinically relevant since
the slightly higher hydrodolasetron exposures in CYP2D6
EMs in the presence of casopitant were still substantially
lower than those observed in CYP2D6 PMs with dolasetron
alone. While the interaction observed in EMs and PMs was
not as anticipated, the changes in AUC in both groups were
small (<25%) and are likely to reflect the small subject
numbers in each population, subject to subject variability
and the ability of hydrodolasetron to be metabolized by
multiple CYP enzymes.
When granisetron, which is primarily metabolized by
CYP1A1 and CYP3A4, was coadministered with casopi-
tant, changes in exposure were minor (mean increases in
exposure of less than or equal to 11%) and were not
associated with any change in the safety or adverse-event
profile of granisetron that would not be considered
clinically important given that the within-subject variability
for granisetron exposure is approximately 23% (see
“Statistics”).
Coadministration of casopitant and dolasetron or grani-
setron was well tolerated. All adverse events were mild or
moderate in intensity, and all events resolved. The ECG
effects of hydrodolasetron are dose dependent and were
reported to be observed at single doses greater than 200 mg
[19]. Since the recommended oral dose of dolasetron of
100 mg was utilized in the present study, increase in plasma
concentration of up to twofold or 100% (equal to a 200-mg
dose) can be considered clinically unimportant for the 100-
mg dose. The maximum increase in Cmax seen in the
present study was only 31%. Moreover, no apparent
differences in cardiac function (QTc, bradycardia) occurred
when either dolasetron or granisetron was coadministered
with casopitant. Similarly, no effect on cardiac function of
casopitant coadministered with the serotonin antagonist
ondansetron was recently reported [15]. Further, Li et al.
[19] have reported that there is no effect of a similar NK-1
receptor antagonist, aprepitant, on the PK and cardiac
safety profile of hydrodolasetron in CYP2D6 EMs or PMs.
Consequently, these findings, coupled with no clinically
important increase in hydrodolasetron or granisetron expo-
sure in the presence of casopitant, suggest that casopitant is
unlikely to increase the potential for either of these drugs to
elicit life-threatening arrhythmias. Similar insignificant
changes in ondansetron exposure and safety have been
observed in another drug–drug interaction study with
casopitant [14]. While the majority of subjects in the
dolasetron cohort were male and the majority in the
granisetron cohort were female, previous unpublished studies
have shown that casopitant pharmacokinetics is similar in
male and female subjects. Casopitant, therefore, would be
expected to have a similar inhibitory potential on CYP3A-
metabolizing enzymes and result in similar observations to
those observed in the current study.
Given that palonosetron is also metabolized by the same
mixed CYP enzymes as other 5-HT3 receptor antagonists
(CYP2D6, 3A4, 1A2) and is administered intravenously
[22], no drug–drug interaction of clinical relevance between
casopitant and palonosetron would be anticipated. Indeed, a
study investigating the concomitant administration of
another NK-1 receptor antagonist, aprepitant, and IV
Table 3 Adverse events reported in two or more subjects
Dolasetron,
N=18, n (%)
Dolasetron + casopitant,
N=18, n (%)
Granisetron,
N=19, n (%)
Granisetron + casopitant,
N=18, n (%)
Subjects with any adverse event 5 (28%) 4 (22%) 11 (58%) 7 (39%)
Headache 4 (22%) 1 (6%) 5 (26%) 2 (11%)
Somnolence 1 (6%) 3 (17%) 0 5 (28%)
Dizziness 1 (6%) 1 (6%) 1 (5%) 1 (6%)
Constipation 0 0 6 (32%) 1 (6%)
1192 Support Care Cancer (2009) 17:1187–1193palonosetron concluded that no dosage adjustment of either
agent was needed when administered together [27]. The
current study demonstrates that casopitant coadministered
with the 5-HT3 receptor antagonists dolasetron or granise-
tron does not result in clinically relevant changes in the
pharmacokinetics or safety of these agents and that these
combinations may be used in antiemetic regimens for the
prevention of PONV or CINV.
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